Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Leap Therapeutics's Enterprise Value is $12.83 Mil.
Leap Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-81.41 Mil. Therefore, Leap Therapeutics's EV-to-EBIT ratio for today is -0.16.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Leap Therapeutics's Enterprise Value is $12.83 Mil.
Leap Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-81.20 Mil. Therefore, Leap Therapeutics's EV-to-EBITDA ratio for today is -0.16.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Leap Therapeutics's Enterprise Value is $12.83 Mil.
Leap Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Leap Therapeutics's EV-to-Revenue ratio for today is .
Leap Therapeutics Enterprise Value Historical Data
The historical data trend for Leap Therapeutics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Leap Therapeutics's Enterprise Value
For the Biotechnology subindustry, Leap Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Leap Therapeutics's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Leap Therapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Leap Therapeutics's Enterprise Value falls into.
Leap Therapeutics Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Leap Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Leap Therapeutics (NAS:LPTX) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Leap Therapeutics's current Enterprise Value is $12.83 Mil.
Leap Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-81.41 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Leap Therapeutics's current Enterprise Value is $12.83 Mil.
Leap Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-81.20 Mil.
Leap Therapeutics's current Enterprise Value is $12.83 Mil.
Leap Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Leap Therapeutics Enterprise Value Related Terms
Thank you for viewing the detailed overview of Leap Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Leap Therapeutics (Leap Therapeutics) Business Description
Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P204,and P205.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LPTX has been successfully added to your 